98%
921
2 minutes
20
-Aminosalicylic acid (PAS) is a second-line anti-tubercular drug that is used for the treatment of drug-resistant tuberculosis (TB). PAS efficacy in the treatment of TB is limited by its lower potency against relative to many other drugs in the TB treatment arsenal. It is known that intrinsic metabolites, such as, -aminobenzoic acid (PABA) and methionine, antagonize PAS and structurally related anti-folate drugs. While the basis for PABA-mediated antagonism of anti-folates is understood, the mechanism for methionine-based antagonism remains undefined. In the present study, we used both targeted and untargeted approaches to identify factors associated with methionine-mediated antagonism of PAS activity. We found that synthesis of folate precursors as well as a putative amino acid transporter, designated MetM, play crucial roles in this process. Disruption of by transposon insertion resulted in a ≥30-fold decrease in uptake of methionine in BCG, indicating that is the major facilitator of methionine transport. We also discovered that intracellular biotin confers intrinsic PAS resistance in a methionine-independent manner. Collectively, our results demonstrate that methionine-mediated antagonism of anti-folate drugs occurs through sustained production of folate precursors.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240602 | PMC |
http://dx.doi.org/10.3389/fcimb.2018.00399 | DOI Listing |
Arch Pharm (Weinheim)
September 2025
Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut, Egypt.
Nitazoxanide (NTZ), an FDA-approved drug, served as the framework for synthesizing 22 new broad-spectrum antimicrobial agents from 4-aminosalicylic acid via protection-deprotection, Staudinger reduction, Clauson-Kaas pyrrole synthesis, and nucleophilic substitution. These compounds were evaluated for antibacterial, antimycobacterial, and antitrypanosomal activities. Several compounds, particularly 10, 11, 13, and 22, surpassed the antibacterial activity of NTZ and its active metabolite tizoxanide (TIZ) against all tested pathogens, with MICs ranging from 1.
View Article and Find Full Text PDFUlcerative colitis (UC) predominantly affects the colon; upper gastrointestinal involvement (UGI) has been reported, but no established treatments exist. We report two cases of UC with concomitant UGI that showed positive responses to vedolizumab therapy. Case 1 involved a 29-year-old man who developed continuous inflammation extending from the stomach to the jejunum 1 month after an initial UC diagnosis.
View Article and Find Full Text PDFIntern Med
September 2025
Department of Rheumatology, University of Yamanashi Hospital, Japan.
Background Iguratimod (IGU) is a synthetic disease-modifying anti-rheumatic drug that is mainly used in East Asia. Kidney impairment related to IGU may be under-recognized, and its proportion, severity, and risk factors remain unclear. Objectives To assess the influence of IGU on the kidney function among RA) and to clarify the risk factors associated with kidney impairment.
View Article and Find Full Text PDFClin Pharmacol Ther
August 2025
Genentech Inc., South San Francisco, California, USA.
Sulfasalazine, a cornerstone therapy for inflammatory bowel disease, relies on bacterial azo-reduction to release its active component, 5-aminosalicylic acid (5-ASA), which is further metabolized into inactive N-acetyl-5-aminosalicylic acid (N-acetyl-5-ASA) by bacterial N-acetyltransferase. Due to complex pharmacokinetics, patient-specific microbial metabolism, and the lack of accurate, convenient direct sampling method for gastrointestinal drug concentrations, sulfasalazine clinical efficacy remains variable. The CapScan® luminal sampling device enables region-specific, minimally invasive collection of intestinal contents.
View Article and Find Full Text PDFBackground: Adherence to 5-aminosalicylic acid (5-ASA), an anchor drug for ulcerative colitis (UC), affects remission maintenance. This study aimed to investigate the current status of adherence to 5-ASA and identify the factors associated with adherence.
Methods: We enrolled UC patients whose primary maintenance therapy was oral 5-ASA at our hospital between January 2017 and December 2018.